Nevro Corp at Citi Healthcare & Medtech Conference Transcript
So welcome back or welcome again. And so for the second session this morning, we have the management of Nevro. Rod and Julie, welcome. And for those of you who don't know me, I'm Joanne Wuensch, the medical technology analyst at Citi.
Questions & Answers
So a few things have been going on for Nevro over the last couple of years. I think it would be great to sort of level set us. Where do you think the spinal cord stimulation market is? And where do you think Nevro is within that market?
Yes. So I mean it's been an interesting couple of years, obviously, for all of us. I think the pain space has been particularly interesting, and it was certainly impacted by the pandemic and the staffing issues that you've heard from a lot of companies.
So a couple of things I'd say. So first of all, the core back and leg business was obviously impacted
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
